

# Global Artificial Intelligence (AI) in Clinical Trials Market

<https://marketpublishers.com/r/G3AB0B0F8177EN.html>

Date: October 2025

Pages: 153

Price: US\$ 4,650.00 (Single User License)

ID: G3AB0B0F8177EN

## Abstracts

The global market for Artificial Intelligence (AI) in Clinical Trials was valued at \$2 billion in 2024 and is estimated to increase from \$2.4 billion in 2025 to reach \$6.5 billion by 2030, at a compound annual growth rate (CAGR) of 22.6% from 2025 through 2030.

Clinical trials have started leveraging advanced algorithms and machine learning (ML) to streamline trial design, patient recruitment, monitoring, and data analysis. The use of AI increases efficiency, reduces timelines, and supports precision medicine through real-time, data-driven decision-making. The global market for AI in clinical trials was valued at \$REDACTED billion in 2024 and is expected to reach \$REDACTED billion by the end of 2030, at a CAGR of REDACTED% during the forecast period.

The use of AI in clinical trials is changing drug development by enabling faster, more accurate, and data-driven decision-making at every research stage. Technologies such as ML, natural language processing (NLP) and predictive analytics help researchers find patients, design protocols and select trial sites, as well as improve trial operations, reduce human error, and accelerate the delivery of effective treatments. AI is also used to analyze complex datasets, including electronic health records (EHRs), genomics, and wearable device outputs, making trials more adaptable and focused.

## Report Scope

The report examines trends in the global market for AI in clinical trials. It segments the global market by component, phase, deployment mode, therapeutic area and end user. It also provides insights into key emerging trends and potential growth drivers. Components consist of software and services. Deployment mode include cloud, on-premise, and hybrid. Therapeutic areas include cancers, infectious diseases and

neurological diseases. End users include pharmaceutical and biotech companies, contract research organizations (CROs), and research and academic institutes.

The report's regional analysis covers North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. It evaluates the impact of AI adoption in clinical trials and the market dynamics, including drivers and challenges. The study concludes with an analysis of leading companies in the market and their product portfolios.

It includes global revenue (\$ millions) for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

## **Report Includes**

56 data tables and 52 additional tables

In-depth analysis of the global market for artificial intelligence (AI) in pharmaceutical clinical trials

Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030

Estimates of the market's size and revenue growth prospects, accompanied by a market share analysis by offerings, deployment type, trial phase, therapeutic area, end user and region

Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables

Impact analysis of U.S. tariff laws on AI in the clinical trials market

Insights derived from Porter's Five Forces model, as well as a global supply chain analysis

A look at the regulatory landscape featuring key international and regional regulations and standards for AI adoption

Evaluation of recent patent activity and key granted and published patents

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Company profiles of major players within the industry, including IQVIA, Medidata, Saama, Merative, and Nvidia Corp.

## Contents

### **CHAPTER 1 EXECUTIVE SUMMARY**

Market Outlook  
Scope of Report  
Market Summary

### **CHAPTER 2 MARKET OVERVIEW**

Overview  
Future Outlook  
Macroeconomic Factors  
Global GDP Growth  
Demographic Factors  
Impact of U.S. Tariffs  
Porter's Five Forces Analysis  
Impact of AI Adoption on Clinical Trials Market  
Overview  
Use Cases/Case Studies  
Use Case 1: Oncology Patient Recruitment  
Use Case 2: Accelerating Data Processing in Infectious Disease Vaccine Trials  
Use Case 3: Enhancing Patient Retention in Alzheimer's Disease Trials  
AI Adoption: Clinical Trials  
Adoption Trends at Regional/Country Levels  
AI Disruption Trends  
Impact of AI on Industry Verticals  
Impact of AI on the Value Chain  
Market Spending and Investment  
Market Spending and Forecasting Analysis  
Venture Capital Investment in AI Focused on Clinical Trials

### **CHAPTER 3 MARKET DYNAMICS**

Market Drivers  
Need for a Faster Drug Development Process  
AI-driven Clinical Trials  
Advanced Data Handling for Complex Clinical Input  
Market Restraints

Data Privacy and Security Concerns  
Regulatory Uncertainties  
High Costs and Technical Complexity  
Market Opportunities  
Accelerated Trials Through Adaptive AI Design  
AI-Augmented Remote Patient Monitoring

## **CHAPTER 4 REGULATORY LANDSCAPE**

Regulatory Framework

## **CHAPTER 5 EMERGING TECHNOLOGIES**

Overview  
Emerging Technologies  
Machine Learning for Predictive Analytics and Stratification  
Digital Twin Technology  
NLP for Extracting Insights from Unstructured Data  
AI-Powered Trial Design and Optimization  
Blockchain for Secure Clinical Data Management  
Decentralized and Virtual Trial Platforms  
Remote Monitoring Via Wearable Technologies  
Generative AI for Protocol Authoring  
Real-World Evidence Integration in Clinical Trials  
Cloud-based AI Platforms for Scalable Deployment  
Clinical Trial Analysis  
Takeaways

## **CHAPTER 6 MARKET SEGMENTATION ANALYSIS**

Segmentation Breakdown  
Global Market for AI in Clinical Trials, by Component  
Takeaways  
Software  
Services  
Global AI in Clinical Trials Market, by Phase  
Takeaways  
Phase III  
Phase II Trials

Phase I

Phase IV Clinical Trials

Global Market for AI in Clinical Trials, by Deployment Mode

Takeaways

Cloud

On-premise

Hybrid Deployments

Global Market for AI in Clinical Trials, by Therapeutic Area

Takeaways

Oncology

Infectious Disease Clinical Trials

Neurological Diseases

Other Conditions

Global Market for AI in Clinical Trials, by End User

Takeaways

Pharmaceutical and Biotech Companies

Contract Research Organizations

Research and Academic Institutes

Other End Users

Geographic Breakdown

North America

Europe

Asia-Pacific

Middle East and Africa

South America

## **CHAPTER 7 COMPETITIVE INTELLIGENCE**

Overview

## **CHAPTER 8 SUSTAINABILITY IN AI IN CLINICAL TRIALS: ESG PERSPECTIVE**

Sustainability Trends and AI Initiatives

Concluding Remarks

## **CHAPTER 9 APPENDIX**

Methodology

Sources

Abbreviations

Company Profiles

AICURE

CONCERTAI

DNANEXUS INC.

INSILICO MEDICINE

INTELLIGENCIA AI

IQVIA

MEDIDATA

MERATIVE

NVIDIA CORP.

PHESI

SAAMA

TEMPUS

TRINETX LLC

TRIOMICS

UNLEARN.AI INC.

Emerging Start-ups/ Market Disruptors

## List Of Tables

### LIST OF TABLES

Summary Table : Global Market for AI in Clinical Trials, by Region, Through 2030

Table 1 : Real GDP Growth, by Country, 2022-2025

Table 2 : Venture Capital Funding for U.S. Companies on AI for Clinical Trials

Table 3 : VC Investment in AI Focused on Clinical Trials

Table 4 : Regulations Pertaining to AI in Clinical Trials

Table 5 : Clinical Trials Studies

Table 6 : Global Market for AI in Clinical Trials, by Component, Through 2030

Table 7 : Global Market for AI Software in Clinical Trials, by Region, Through 2030

Table 8 : Global Market for Services Related to AI in Clinical Trials, by Region, Through 2030

Table 9 : Global Market for AI in Clinical Trials, by Phase, Through 2030

Table 10 : Global Market for AI in Phase III Clinical Trials, by Region, Through 2030

Table 11 : Global Market for AI in Phase II Clinical Trials, by Region, Through 2030

Table 12 : Global Market for AI in Phase I Clinical Trials, by Region, Through 2030

Table 13 : Global Market for AI in Phase IV Clinical Trials, by Region, Through 2030

Table 14 : Global Market for AI in Clinical Trials, by Deployment Mode, Through 2030

Table 15 : Global Market for Cloud Deployments of AI in Clinical Trials, by Region, Through 2030

Table 16 : Global Market for On-Premise Deployments of AI in Clinical Trials, by Region, Through 2030

Table 17 : Global Market for Hybrid Deployments of AI in Clinical Trials, by Region, Through 2030

Table 18 : Global Market for AI in Clinical Trials, by Therapeutic Area, Through 2030

Table 19 : Global Market for AI in Oncology Clinical Trials, by Region, Through 2030

Table 20 : Global Market for AI in Infectious Disease Clinical Trials, by Region, Through 2030

Table 21 : Global Market for AI in Neurological Disease Clinical Trials, by Region, Through 2030

Table 22 : Global Market for AI in Clinical Trials for Other Conditions, by Region, Through 2030

Table 23 : Global Market for AI in Clinical Trials, by End User, Through 2030

Table 24 : Global Market for AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, Through 2030

Table 25 : Global Market for AI Used in Clinical Trials by CROs, by Region, Through 2030

Table 26 : Global Market for AI Used in Clinical Trials by Research and Academic Institutes, by Region, Through 2030

Table 27 : Global Market for AI Used by Other End Users in Clinical Trials, by Region, Through 2030

Table 28 : Global Market for AI in Clinical Trials, by Region, Through 2030

Table 29 : North American Market for AI in Clinical Trials, by Component, Through 2030

Table 30 : North American Market for AI in Clinical Trials, by Phase, Through 2030

Table 31 : North American Market for AI in Clinical Trials, by Deployment Mode, Through 2030

Table 32 : North American Market for AI in Clinical Trials, by Therapeutic Area, Through 2030

Table 33 : North American Market for AI in Clinical Trials, by End User, Through 2030

Table 34 : North American Market for AI in Clinical Trials, by Country, Through 2030

Table 35 : European Market for AI in Clinical Trials, by Component, Through 2030

Table 36 : European Market for AI in Clinical Trials, by Phase, Through 2030

Table 37 : European Market for AI in Clinical Trials, by Deployment Mode, Through 2030

Table 38 : European Market for AI in Clinical Trials, by Therapeutic Area, Through 2030

Table 39 : European Market for AI in Clinical Trials, by End User, Through 2030

Table 40 : European Market for AI in Clinical Trials, by Country, Through 2030

Table 41 : Asia-Pacific Market for AI in Clinical Trials, by Component, Through 2030

Table 42 : Asia-Pacific Market for AI in Clinical Trials, by Phase, Through 2030

Table 43 : Asia-Pacific Market for AI in Clinical Trials, by Deployment Mode, Through 2030

Table 44 : Asia-Pacific Market for AI in Clinical Trials, by Therapeutic Area, Through 2030

Table 45 : Asia-Pacific Market for AI in Clinical Trials, by End User, Through 2030

Table 46 : Asia-Pacific Market for AI in Clinical Trials, by Country, Through 2030

Table 47 : MEA Market for AI in Clinical Trials, by Component, Through 2030

Table 48 : MEA Market for AI in Clinical Trials, by Phase, Through 2030

Table 49 : MEA Market for AI in Clinical Trials, by Deployment Mode, Through 2030

Table 50 : MEA Market for AI in Clinical Trials, by Therapeutic Area, Through 2030

Table 51 : MEA Market for AI in Clinical Trials, by End User, Through 2030

Table 52 : MEA Market for AI in Clinical Trials, by Sub-Region, Through 2030

Table 53 : South American Market for AI in Clinical Trials, by Component, Through 2030

Table 54 : South American Market for AI in Clinical Trials, by Phase, Through 2030

Table 55 : South American Market for AI in Clinical Trials, by Deployment Mode, Through 2030

Table 56 : South American Market for AI in Clinical Trials, by Therapeutic Area, Through 2030

2030

Table 57 : South American Market for AI in Clinical Trials, by End User, Through 2030

Table 58 : South American Market for AI in Clinical Trials, by Country, Through 2030

Table 59 : Global Ranking of Players in AI in Clinical Trials Industry, 2024

Table 60 : Strategic Initiatives, 2024 and 2025

Table 61 : Information Sources Used in Preparing this Report

Table 62 : Abbreviations Used in this Report

Table 63 : AiCure: Company Snapshot

Table 64 : AiCure: Product Portfolio

Table 65 : AiCure: News/Key Developments, 2022

Table 66 : ConcertAI: Company Snapshot

Table 67 : ConcertAI: Product Portfolio

Table 68 : ConcertAI: News/Key Developments, 2023 and 2024

Table 69 : DNAnexus Inc.: Company Snapshot

Table 70 : DNAnexus Inc: Product Portfolio

Table 71 : DNAnexus Inc: News/Key Developments, 2024 and 2025

Table 72 : Insilico Medicine: Company Snapshot

Table 73 : Insilico Medicine: Product Portfolio

Table 74 : Insilico Medicine: News/Key Developments, 2023-2025

Table 75 : Intelligencia AI: Company Snapshot

Table 76 : Intelligencia AI: Product Portfolio

Table 77 : IQVIA: Company Snapshot

Table 78 : IQVIA: Financial Performance, FY 2023 and 2024

Table 79 : IQVIA: Product Portfolio

Table 80 : IQVIA: News/Key Developments, 2025

Table 81 : Medidata: Company Snapshot

Table 82 : Medidata: Product Portfolio

Table 83 : Medidata: News/Key Developments, 2023-2025

Table 84 : Merative: Company Snapshot

Table 85 : Merative: Product Portfolio

Table 86 : Nvidia Corp.: Company Snapshot

Table 87 : Nvidia Corp.: Financial Performance, FY 2023 and 2024

Table 88 : Nvidia Corp.: Product Portfolio

Table 89 : Nvidia Corp.: News/Key Developments, 2023–2025

Table 90 : Phesi: Company Snapshot

Table 91 : Phesi: Product Portfolio

Table 92 : Phesi: News/Key Developments, 2022-2025

Table 93 : Saama: Company Snapshot

Table 94 : Saama: Product Portfolio

Table 95 : Saama: News/Key Developments, 2023 and 2024

Table 96 : Tempus: Company Snapshot

Table 97 : Tempus: Product Portfolio

Table 98 : Tempus: News/Key Developments, 2022-2025

Table 99 : TriNetX LLC.: Company Snapshot

Table 100 : TriNetX LLC: Product Portfolio

Table 101 : TriNetX LLC: News/Key Developments, 2025

Table 102 : Triomics: Company Snapshot

Table 103 : Triomics: Product Portfolio

Table 104 : Unlearn.ai Inc.: Company Snapshot

Table 105 : Unlearn.ai Inc.: Product Portfolio

Table 106 : Unlearn.ai Inc.: News/Key Developments, 2022 and 2025

Table 107 : Emerging Startups

## List Of Figures

### LIST OF FIGURES

Summary Figure : Global Market Shares of AI in Clinical Trials, by Region, 2024

Figure 1 : Porter's Five Forces Analysis

Figure 2 : Market Dynamics of Artificial Intelligence in Clinical Trials Market

Figure 3 : Global Market Shares of AI in Clinical Trials, by Component, 2024

Figure 4 : Global Market Shares of AI Software in Clinical Trials, by Region, 2024

Figure 5 : Global Market Shares of Services Related to AI in Clinical Trials, by Region, 2024

Figure 6 : Global Market Shares of AI in Clinical Trials, by Phase, 2024

Figure 7 : Global Market Shares of AI in Phase III Clinical Trials, by Region, 2024

Figure 8 : Global Market Shares of AI in Phase II Clinical Trials, by Region, 2024

Figure 9 : Global Market Shares of AI in Phase I Clinical Trials, by Region, 2024

Figure 10 : Global Market Shares of AI in Phase IV Clinical Trials, by Region, 2024

Figure 11 : Global Market Shares of AI in Clinical Trials, by Deployment Mode, 2024

Figure 12 : Global Market Shares of Cloud Deployments of AI in Clinical Trials, by Region, 2024

Figure 13 : Global Market Shares of On-Premise Deployments of AI in Clinical Trials, by Region, 2024

Figure 14 : Global Market Shares of Hybrid Deployments of AI in Clinical Trials, by Region, 2024

Figure 15 : Global Market Shares of AI in Clinical Trials, by Therapeutic Area, 2024

Figure 16 : Global Market Shares of AI in Oncology Clinical Trials, by Region, 2024

Figure 17 : Global Market Shares of AI in Infectious Disease Clinical Trials, by Region, 2024

Figure 18 : Global Market Shares of AI in Neurological Disease Clinical Trials, by Region, 2024

Figure 19 : Global Market Shares of AI in Clinical Trials for Other Conditions, by Region, 2024

Figure 20 : Global Market Shares of AI in Clinical Trials, by End User, 2024

Figure 21 : Global Market Shares of AI Used in Clinical Trials by Pharmaceutical and Biotech Companies, by Region, 2024

Figure 22 : Global Market Shares of AI Used in Clinical Trials by CROs, by Region, 2024

Figure 23 : Global Market Shares of AI Used in Clinical Trials by Research and Academic Institutes, by Region, 2024

Figure 24 : Global Market Shares of AI Used by Other End Users in Clinical Trials, by

Region, 2024

Figure 25 : Global Market Shares of AI in Clinical Trials, by Region, 2024

Figure 26 : North American Market Shares of AI in Clinical Trials, by Country, 2024

Figure 27 : European Market Shares of AI in Clinical Trials, by Country, 2024

Figure 28 : Asia-Pacific Market Shares of AI in Clinical Trials, by Country, 2024

Figure 29 : MEA Market Shares of AI in Clinical Trials, by Sub-Region, 2024

Figure 30 : South American Market Shares of AI in Clinical Trials, by Country, 2024

Figure 31 : IQVIA: Revenue Shares, by Business Unit, FY 2024

Figure 32 : IQVIA: Revenue Shares, by Country/Region, FY 2024

Figure 33 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024

Figure 34 : Nvidia Corp.: Revenue Share, by Country/Region, FY 2024

## I would like to order

Product name: Global Artificial Intelligence (AI) in Clinical Trials Market

Product link: <https://marketpublishers.com/r/G3AB0B0F8177EN.html>

Price: US\$ 4,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3AB0B0F8177EN.html>